# To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

> **NCT07374406** · PHASE1 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Epaminurad 9 mg (JW Pharmaceutical)
- **DRUG:** Epaminurad 9 mg (Shanghai STA Pharmaceutical)

## Key facts

- **NCT ID:** NCT07374406
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-02-02
- **Primary completion:** 2026-02-19
- **Final completion:** 2026-02-24
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07374406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07374406, "To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT07374406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*